Effects of RXC007, a highly potent and selective ROCK2 inhibitor, in ex-vivo and in vivo models of pulmonary fibrosis.
A. Gambardella (Macclesfield, United Kingdom), N. Guisot (Macclesfield, United Kingdom), P. Bunyard (Macclesfield, United Kingdom), E. Offer (Macclesfield, United Kingdom)
Source: International Congress 2022 – Interstitial lung diseases diagnosis in the COVID-19 era: new tools for new challenges
 
Rating: 
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
A. Gambardella (Macclesfield, United Kingdom), N. Guisot (Macclesfield, United Kingdom), P. Bunyard (Macclesfield, United Kingdom), E. Offer (Macclesfield, United Kingdom). Effects of RXC007, a highly potent and selective ROCK2 inhibitor, in ex-vivo and in vivo models of pulmonary fibrosis.. 453
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
|
|